Guanfacine ER Formulation
No, guanfacine extended-release (Intuniv) does not come as a sprinkle formulation or liquid suspension—it is only available as extended-release tablets that must be swallowed whole. 1
Available Formulations
According to the FDA drug label, Intuniv is manufactured exclusively as extended-release matrix tablets in four strengths: 1 mg, 2 mg, 3 mg, and 4 mg 1. The tablets contain guanfacine hydrochloride in a matrix formulation with hypromellose, methacrylic acid copolymer, lactose, povidone, crospovidone, microcrystalline cellulose, fumaric acid, and glyceryl behenate 1.
Critical Administration Requirements
The tablets must be swallowed whole with water, milk, or other liquid and cannot be crushed, chewed, or broken 1. This is a non-negotiable requirement because:
- Crushing or breaking the tablets would destroy the extended-release mechanism
- This would increase the rate of drug release, potentially causing dangerous adverse effects
- The extended-release formulation is specifically designed for once-daily dosing with controlled drug delivery over 24 hours 1
Clinical Implications
For patients who cannot swallow tablets whole (young children, those with dysphagia), guanfacine ER is not an appropriate medication choice. In such cases, clinicians should consider:
- Alternative ADHD medications that come in liquid or sprinkle formulations (such as certain methylphenidate or amphetamine preparations)
- Immediate-release guanfacine (Tenex), though this is not FDA-approved for ADHD and requires multiple daily doses
- Behavioral interventions as first-line treatment until the patient can manage tablet administration
The evidence consistently describes guanfacine ER as available only in tablet form across multiple guidelines and research studies 2.